Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach
- Authors
- Kim Y.H.; Ajani J.A.; Ota D.M.; Lynch P.; Roth J.A.
- Issue Date
- 1995
- Keywords
- carcinoembryonic antigen; preoperative chemotherapy; resectable adenocarcinoma of the esophagus and the stomach
- Citation
- Cancer, v.75, no.2, pp 451 - 456
- Pages
- 6
- Indexed
- SCOPUS
- Journal Title
- Cancer
- Volume
- 75
- Number
- 2
- Start Page
- 451
- End Page
- 456
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/26405
- DOI
- 10.1002/1097-0142(19950115)75:2<451::AID-CNCR2820750207>3.0.CO;2-U
- ISSN
- 0008-543X
1097-0142
- Abstract
- Background. Adenocarcinomas of the esophagus and the stomach are highly virulent and remain a major health problem worldwide; 5‐year survival rates have not changed in the past 30 years. Recently, preoperative chemotherapy has been used to treat these adenocarcinomas. The authors evaluated the usefulness of serial serum carcinoembryonic antigen (CEA) levels in diagnosing these patients and compared the prognosis of patients with high or normal CEA levels. Methods. Ninety consecutive patients with potentially resectable adenocarcinoma of the esophagus or stomach treated with preoperative chemotherapy were evaluated. Serum CEA levels were determined before registration, after each chemotherapy course, every 3 months for the first year after completion of all therapy, and every 6 months thereafter for 5 years. Results. The CEA positivity rate before chemotherapy was 22.2% (20/90); after chemotherapy, it dropped to 10.9% (9/82). An increasing CEA level predicted relapse and correlated well with liver, lung, or pleural involvement in some patients. Most patients with peritoneal involvement did not show elevated levels of CEA. Clinical responses correlated with declining levels of CEA in the patients who showed a negative conversion in CEA level after chemotherapy. Conclusions. An elevated serum CEA level enabled early detection of relapse in the absence of clinical symptoms in patients with adenocarcinoma of the esophagus or the stomach. The level of CEA was also useful in monitoring the response to chemotherapy in patients who had a high CEA level before treatment. Although the pre‐ and postchemotherapy CEA‐positive group had a higher relapse rate than that of other group, the CEA level did not predict resectability or survival. Future research with labeled monoclonal anti‐CEA antibodies may prove useful for certain groups of patients. Cancer 1995;75:451‐6. Copyright © 1995 American Cancer Society
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Medical Oncology and Hematology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.